Taipei, a pharmaceutical company called AnHorn Medicines revealed on June 22, 2026, that its primary neuroprotective drug AH-008, created to combat chemotherapy-induced peripheral neuropathy (CIPN), has successfully reached significant regulatory landmarks. The drug has obtained approval as an Investigational New Drug (IND)...